ArticleExperimental hematology & oncology2024

Novel agents and regimens in relapsed or refractory peripheral T-cell lymphoma: latest updates from 2023 ASH annual meeting.

Huageng Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.